Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 20/20 | 0.56 |
| ▸ | ITGA4 | P13612 | 20/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zaurategrast SCHEMBL5571298 | 1.00 | ITGB1 (0.56) | ITGB1ITGA4CYP3A4CYP2C9 | |
| Ucb-1184197 SCHEMBL3833843 | 0.90 | ITGB1 (0.47) | ITGB1ITGA4CYP3A4CYP2C9 | |
| Ucb-1184197 SCHEMBL6131680 | 0.90 | ITGB1 (0.47) | ITGB1ITGA4CYP3A4CYP2C9 | |
| Ucb-1184197 SCHEMBL29373839 | 0.90 | ITGB1 (0.47) | ITGB1ITGA4CYP3A4CYP2C9 | |
| SCHEMBL2990251 | 0.90 | ITGB1 (0.56) | ITGB1ITGA4CYP3A4CYP2C9 | |
| SCHEMBL5573810 | 0.89 | ITGB1 (0.45) | ITGB1ITGA4CYP3A4CYP2C9 | |
| SCHEMBL2984149 | 0.89 | ITGB1 (0.55) | ITGB1ITGA4CYP3A4CYP2C9 | |
| SCHEMBL3884133 | 0.87 | ITGB1 (0.58) | ITGB1ITGA4CYP3A4CYP2C9 | |
| SCHEMBL2978337 | 0.87 | ITGB1 (0.58) | ITGB1ITGA4CYP3A4CYP2C9 | |
| SCHEMBL2978998 | 0.86 | ITGB1 (0.55) | ITGB1ITGA4CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230107927-A1 | METHODS OF TREATING IATROGENIC AUTOIMMUNE COLITIS | FIRST WAVE BIO, INC. | 2023-04-06 | — | — | US | claimed |
| US-20230033021-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN INTEGRIN INHIBITOR | GLAS USA LLC | 2023-02-02 | — | — | US | claimed |
| US-20140357654-A1 | METHODS OF TREATING SCHIZOPHRENIA WITH PHENYLALANINE ENAMIDE DERIVATIVE INHIBITORS OF a4 INTEGRIN POSSESSING A CYCLOBUTENE GROUP | AESTUS THERAPEUTICS, INC. (US) | 2014-12-04 | — | — | US | claimed |
| EP-2775840-A1 | METHODS OF TREATING SCHIZOPHRENIA WITH PHENYLALANINE ENAMIDE DERIVATIVE INHIBITORS OF 4 INTEGRIN POSSESSING A CYCLOBUTENE GROUP | Aestus Therapeutics, Inc. (US) | 2014-09-17 | — | — | EP | claimed |
| WO-2013070842-A1 | METHODS OF TREATING SCHIZOPHRENIA WITH PHENYLALANINE ENAMIDE DERIVATIVE INHIBITORS OF α4 INTEGRIN POSSESSING A CYCLOBUTENE GROUP | AESTUS THERAPEUTICS, INC. (US) | 2013-05-16 | — | — | WO | claimed |
| US-7645770-B2 | Phenylalanine enamide derivatives | UCB PHARMA S.A. (BE) | 2010-01-12 | — | — | US | claimed |
| US-20090105291-A1 | Phenylalanine Enamide Derivatives | RIGEL PHARMACEUTICALS, INC. (US) | 2009-04-23 | — | — | US | claimed |
| US-7501437-B2 | Phenylalanine enamide derivatives | UCB PHARMA, S.A. (BE) | 2009-03-10 | — | — | US | claimed |
| US-20070167483-A1 | 2-[(2-Isopropylsulfanyl-3-oxo-spiro[3.5]non-1-en-1-yl)amino]-3-[4-([2,7]naphthyridin-1-ylamino)phenyl]propanoic acid; compounds can inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders | UCB PHARMA S.A. (BE) | 2007-07-19 | — | — | US | claimed |
| EP-1525204-B1 | PHENYLALANINE ENAMIDE DERIVATIVES | CELLTECH R&D LTD (GB) | 2007-07-18 | — | — | EP | claimed |
| EP-1780201-A2 | PHENYLALANINE ENAMIDE DERIVATIVES POSSESSING A CYCLOBUTENE GROUP, FOR USE AS INTEGRIN INHIBITORS | Celltech R&D Limited (GB) | 2007-05-02 | — | — | EP | claimed |
| EP-1370531-B1 | PHENYLALANINE ENAMIDE DERIVATIVES POSSESSING A CYCLOBUTENE GROUP, FOR USE AS INTEGRIN INHIBITORS | CELLTECH R&D LTD (GB) | 2007-02-28 | — | — | EP | claimed |
| US-6951943-B2 | Process for the preparation of phenylalanine enamide derivatives | CELLTECH R & D LIMITED (GB) | 2005-10-04 | — | — | US | claimed |
| EP-1525204-A1 | PHENYLALANINE ENAMIDE DERIVATIVES | Celltech R & D Limited (GB) | 2005-04-27 | — | — | EP | claimed |
| US-6878718-B2 | Phenylalanine enamide derivatives | CELLTECH R&D LIMITED (GB) | 2005-04-12 | — | — | US | claimed |
| US-20050038084-A1 | Phenylalanine enamide derivatives | CELLTECH R&D LIMITED | 2005-02-17 | — | — | US | claimed |
| US-6835738-B1 | Phenylalanine enamide derivatives | CELLTECH R&D LIMITED (GB) | 2004-12-28 | — | — | US | claimed |
| US-20040073033-A1 | Process for the preparation of phenylalanine enamide derivatives | UCB PHARMA S.A. (BE) | 2004-04-15 | — | — | US | claimed |
| WO-2004007494-A1 | PHENYLALANINE ENAMIDE DERIVATIVES | CELLTECH R & D LIMITED (GB) | 2004-01-22 | — | — | WO | claimed |
| US-20020169336-A1 | Phenylalanine enamide derivatives | UCB PHARMA S.A. (BE) | 2002-11-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230033021-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN INTEGRIN INHIBITOR | ITGAL, ITGB2, ITGB1 | ITGB1 3/4885ITGA4 17/4885CYP3A4 2163/4885 |
| US-20140357654-A1 | METHODS OF TREATING SCHIZOPHRENIA WITH PHENYLALANINE ENAMIDE DERIVATIVE INHIBITORS OF a4 INTEGRIN POSSESSING A CYCLOBUTENE GROUP | ITGA4, ITGB4, EPB41 | ITGB1 19/4885ITGA4 1/4885CYP3A4 1346/4885 |
| US-20090105291-A1 | Phenylalanine Enamide Derivatives | PAH, HRH3, PRLHR | ITGB1 100/4885ITGA4 513/4885CYP3A4 2115/4885 |
| US-20040073033-A1 | Process for the preparation of phenylalanine enamide derivatives | NPY2R, NPY1R, NPR1 | ITGB1 4148/4885ITGA4 3960/4885CYP3A4 179/4885 |
| US-20050038084-A1 | Phenylalanine enamide derivatives | PAH, ARRB1, ACVR2B | ITGB1 34/4885ITGA4 316/4885CYP3A4 1873/4885 |
| US-20020169336-A1 | Phenylalanine enamide derivatives | CCR1, AHR, PAH | ITGB1 61/4885ITGA4 443/4885CYP3A4 2065/4885 |
| US-20070167483-A1 | 2-[(2-Isopropylsulfanyl-3-oxo-spiro[3.5]non-1-en-1-yl)amino]-3-[4-([2,7]naphthyridin-1-ylamino)phenyl]propanoic acid; compounds can inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders | ITGB2, VCAM1, ITGB1 | ITGB1 3/4885ITGA4 40/4885CYP3A4 2977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.